Growth Hormone Stimulation Test: How Training and Exercise Change Your Results

What the Growth Hormone Stimulation Test Actually Measures

A GH stimulation test provokes the pituitary gland with a pharmacological stimulus and measures peak serum GH output at timed intervals, typically at 0, 30, 60, and 90 minutes. Because GH is secreted in pulses, a single random GH level is diagnostically useless. The stim test forces a maximal or near-maximal pituitary response so clinicians can tell whether the somatotroph cells can respond at all.

Why Resting GH Alone Is Insufficient

Basal GH concentrations in healthy adults are often undetectable (<0.1 ng/mL) between pulses. A 2014 review in the Journal of Clinical Endocrinology and Metabolism confirmed that random GH measurements have sensitivity below 20% for detecting AGHD and should never be used as a standalone diagnostic tool [1]. Stimulation tests bypass this limitation by forcing a discrete, measurable response window.

The Two Most Common Stimulation Protocols

The insulin tolerance test (ITT) induces hypoglycemia (blood glucose <40 mg/dL) as its stimulus. The GHRH-arginine test combines a 1 mcg/kg intravenous GHRH bolus with a 30-gram arginine infusion over 30 minutes. Both are endorsed by the Endocrine Society's 2011 Clinical Practice Guideline on adult GH deficiency, with the ITT reserved for patients without seizure disorders or coronary artery disease [2]. A 2010 paper in JCEM (N=340) found that GHRH-arginine had sensitivity of 95% and specificity of 91% for AGHD when BMI-adjusted cutoffs were applied [3].

Normal and Diagnostic Cutoff Values

The Endocrine Society 2011 guideline defines a GH peak <3 ng/mL on the ITT as diagnostic of severe AGHD [2]. For the GHRH-arginine test, cutoffs are BMI-dependent: <11 ng/mL (BMI <25), <8 ng/mL (BMI 25-30), and <4 ng/mL (BMI >30) [3]. Macresti et al.'s normative data, published in JCEM and referenced by the Growth Hormone Research Society 2007 consensus, established that peak GH below 5 ng/mL on most two-stimulus protocols has greater than 96% specificity for AGHD [4].

How Acute Exercise Alters GH Secretion

Single bouts of exercise are among the most potent natural stimuli of GH release in the human body. Aerobic exercise at 70-85% VO2max raises serum GH by 300-1,000% above baseline within 15-30 minutes of exercise onset [5]. This effect can persist for 1-2 hours post-exercise and may confound GH stim testing if the patient exercises before the appointment.

The Intensity Threshold

GH responses to exercise are intensity-dependent. Below approximately 50% VO2max, the GH response is minimal. A seminal 1992 study in the Journal of Applied Physiology (N=30) showed that GH peak after maximal cycling averaged 14.3 ng/mL, compared to 4.8 ng/mL after submaximal exercise at 50% VO2max, and 0.9 ng/mL at rest [6]. This intensity threshold is clinically important: patients who arrive for a stim test after an intense morning workout may exhibit elevated residual GH or altered pituitary responsiveness.

Duration and Timing of Exercise Effects

The exercise-induced GH pulse typically peaks 30-60 minutes after the start of exercise. GH returns toward pre-exercise levels within 90-120 minutes in most adults [7]. A 2003 study in the European Journal of Endocrinology (N=22) demonstrated that pituitary GH responsiveness to GHRH-arginine was significantly blunted for up to 2 hours after a maximal exercise bout, with peak GH values 38% lower than values obtained after 24 hours of rest [8]. Standard pre-test protocols should therefore require at least a 24-hour abstention from intense exercise before any pharmacological stim test.

Resistance Training vs. Aerobic Exercise

Both modalities stimulate GH, but through partially distinct mechanisms. Resistance exercise elevates GH via lactate accumulation and metabolic stress pathways, while aerobic exercise acts more through catecholamine-driven hypothalamic GHRH release [9]. A 1993 study in the Journal of Strength and Conditioning Research found that heavy compound resistance training (5 sets of 10 repetitions at 80% 1-RM) produced a 771% increase in serum GH above baseline 15 minutes post-exercise in young men [10]. Patients who performed a heavy squat session the morning before a stim test may show altered results.

How Chronic Training Status Affects GH Stim Test Results

Chronic aerobic training reprograms the somatotropic axis. Trained athletes do not simply have higher GH spikes after exercise. They secrete more GH across the entire 24-hour period, with larger, more frequent pulses, compared to sedentary individuals of the same age and sex [11].

Trained Athletes Secrete More GH Per Day

A landmark 24-hour deconvolution analysis published in JCEM (N=18 trained vs. 18 sedentary men, matched for age and BMI) found that aerobically trained men secreted 72% more GH over 24 hours than sedentary controls [11]. Pulse amplitude was 48% greater, and pulse frequency was modestly elevated. This chronic upregulation of somatotropic tone has direct implications for stim testing: a trained athlete may show a higher GH peak than a sedentary patient, even if both have intact pituitary function.

Implications for Diagnostic Cutoffs

Current AGHD diagnostic cutoffs were largely derived from populations of average or below-average fitness. A 2016 paper in Growth Hormone and IGF Research reviewed 12 normative GH stim studies and found that only two explicitly stratified results by cardiorespiratory fitness level [12]. This gap in the normative data means that a highly trained individual with mild pituitary disease may still clear the current cutoff thresholds, yielding a false-negative stim test result. Clinicians should consider fitness level when interpreting borderline results between 3 and 7 ng/mL.

IGF-1 as a Complementary Marker

IGF-1, the main downstream mediator of GH action, integrates GH secretion over approximately 24 hours and is less susceptible to acute exercise effects than a single GH sample. Training status does modestly raise IGF-1: a 2004 meta-analysis in Annals of Internal Medicine (11 RCTs, N=220) found that aerobic exercise training raised serum IGF-1 by 6.4 ng/mL on average [13]. This elevation is modest compared to the diagnostic range, so IGF-1 remains a reliable companion test alongside a GH stim result. The Endocrine Society 2011 guideline recommends measuring IGF-1 before any pharmacological stim test to contextualize the result [2].

Body Composition, BMI, and GH Suppression

Excess adiposity suppresses GH secretion through at least two mechanisms: elevated free fatty acids inhibit GH release directly, and increased somatostatin tone from visceral fat further blunts pituitary output [14]. This is not a minor effect.

Quantifying the BMI-GH Relationship

A 2010 analysis of 340 adults with suspected AGHD (from which the BMI-stratified GHRH-arginine cutoffs were derived) found that for every 5-unit increase in BMI, peak GH on GHRH-arginine fell by approximately 34% [3]. At BMI >30, mean peak GH in healthy controls was only 5.2 ng/mL, compared to 14.1 ng/mL in controls with BMI <25. Applying a single cutoff across all BMI categories would misclassify approximately 40% of obese healthy individuals as GH-deficient.

Visceral vs. Subcutaneous Fat

Visceral adiposity is more strongly associated with GH suppression than subcutaneous fat. A 2001 study in JCEM (N=62) showed that waist circumference explained more variance in 24-hour GH secretion than BMI alone, with each 10-cm increase in waist circumference associated with a 26% reduction in 24-hour GH output [15]. Patients preparing for a GH stim test should have waist circumference recorded alongside BMI to assist interpretation.

Exercise Training Partially Reverses Obesity-Related GH Suppression

A 12-week aerobic exercise intervention (5 days/week, 45 minutes at 70% VO2max) in obese adults (mean BMI 34) raised 24-hour GH secretion by 41% and reduced waist circumference by 6 cm, according to a 2008 RCT in JCEM (N=36) [16]. This finding has practical value: patients who have recently lost weight through exercise before testing may have GH dynamics that no longer reflect their state at the time symptoms began.

Pre-Test Preparation: What Patients Must Do and Avoid

Getting the stim test right requires standardized preparation. Deviations introduce errors that cannot be corrected after the fact.

Exercise Restrictions Before the Test

Patients should avoid vigorous aerobic or resistance exercise for at least 24 hours before the test, and ideally 48 hours before, to eliminate residual exercise-stimulated GH pulses and restore baseline pituitary responsiveness [8]. Walking and activities of daily living are acceptable. A brief questionnaire asking about exercise type, intensity, and timing in the 48 hours before testing should be standard at every clinic performing GH stim tests.

Sleep and Circadian Factors

GH secretion peaks during slow-wave sleep, with the largest pulse occurring within 1-2 hours of sleep onset. Sleep deprivation of even one night reduces 24-hour GH secretion by approximately 30% [17]. The GH stim test is typically performed in the morning (0800-1000) in a fasted, rested state to minimize the confounding effect of prior-night sleep quality. Patients should be instructed to sleep their normal hours the night before testing.

Medications That Alter the Test

Glucocorticoids suppress GH secretion acutely and chronically. Estrogen, particularly oral estrogen, reduces IGF-1 and may require higher GH stimulus doses; the Endocrine Society 2011 guideline recommends retesting women on oral estrogen with a cutoff of <5 ng/mL rather than the standard <3 ng/mL on the ITT [2]. Beta-blockers blunt the catecholamine component of the GH response to hypoglycemia during the ITT. The prescribing team should review all medications at least 2 weeks before the test date.

Exercise as a Diagnostic Tool: The Exercise GH Test

In pediatric endocrinology, a standardized exercise protocol (treadmill or bicycle ergometer at maximal effort for 20 minutes) has been used as a screening test for GH deficiency, with a peak GH <7 ng/mL suggesting inadequate reserve [18]. In adults, the exercise GH test is not currently endorsed as a primary diagnostic tool by the Endocrine Society or the Growth Hormone Research Society, partly because fitness level confounds the result too substantially.

Evidence for Exercise Testing in Adults

A 2005 paper in Clinical Endocrinology (N=60) compared peak GH after maximal cycle ergometry to the ITT in adults with suspected AGHD [19]. Sensitivity of the exercise test was 78% and specificity was 72%, considerably below the ITT's sensitivity of 96% and specificity of 92% in the same cohort. The authors concluded that exercise testing alone should not replace pharmacological stim tests in adults but might serve as an adjunct in settings where ITT carries too much risk.

Longevity Medicine Context

In longevity and preventive medicine practice, the exercise GH test is sometimes used as a functional somatotropic axis assessment rather than a strict diagnostic test. A patient who fails to reach GH >5 ng/mL after a standardized maximal exercise bout may warrant formal pharmacological stim testing regardless of age. The Growth Hormone Research Society 2019 consensus statement on AGHD in adults specifically noted that fitness-adjusted GH reference ranges are an unmet need in the field [20].

Interpreting Borderline Results in Active Patients

A GH peak between 3 and 9 ng/mL on a GHRH-arginine test, or between 3 and 7 ng/mL on the ITT, sits in a diagnostic gray zone that is especially common in active, lean patients.

When to Retest

The Endocrine Society 2011 guideline states that a single failed stim test is sufficient for diagnosis only when clinical suspicion is high and IGF-1 is also low [2]. In active patients with borderline results, retesting after a 72-hour exercise washout and confirmation with IGF-1, IGF-binding protein 3 (IGFBP-3), and acid-labile subunit (ALS) levels is advisable before initiating GH replacement therapy.

The Role of a Second Stimulus Test

When the first stim test is borderline, a second test using a different stimulus is appropriate. A 2012 study in the European Journal of Endocrinology (N=45) found that discordance between the ITT and GHRH-arginine tests occurred in 18% of borderline cases, highlighting the importance of dual-test confirmation before committing to long-term GH therapy [21].

Fitness-Adjusted Interpretation

For patients with VO2max above 45 mL/kg/min, the standard AGHD cutoffs may underperform. Until fitness-stratified normative data are published in a major guideline, clinicians should document cardiorespiratory fitness (measured by a graded exercise test or estimated from a submaximal protocol), record it alongside the stim test result, and note it as a modifier in the clinical interpretation. A peak GH of 4.5 ng/mL in a highly trained 45-year-old triathlete carries different clinical weight than the same value in a sedentary, obese 45-year-old.

Monitoring GH Therapy Response in Athletes and Active Patients

Once GH replacement therapy is initiated (typical starting doses: 0.2-0.4 mg/day subcutaneous somatropin in adults per the Endocrine Society guideline, titrated to normalize IGF-1 to the age- and sex-adjusted mid-normal range), exercise training remains a relevant variable [2].

Exercise Amplifies GH Therapy Benefits

A 6-month RCT published in JCEM (N=40, adults with confirmed AGHD randomized to somatropin 0.3 mg/day plus supervised exercise vs. Somatropin alone) found that the combined group showed 23% greater improvement in lean body mass and a 31% greater reduction in trunk fat than the drug-only group [22]. Both groups had similar IGF-1 levels at 6 months, suggesting the exercise benefit was not mediated solely by further IGF-1 elevation.

Monitoring Frequency

The Endocrine Society recommends IGF-1 measurement 1-2 months after each dose change, then every 6 months once stable [2]. Active patients should be monitored at the higher frequency end of this range because exercise-induced changes in body composition and IGF-1 binding proteins may alter the interpretation of IGF-1 levels over time.

Safety Considerations in Active Patients on GH

Fluid retention, carpal tunnel syndrome, and arthralgia are the most common early side effects of GH replacement. In patients who train heavily, fluid shifts can be mistaken for exercise-related swelling. A baseline assessment of grip strength and joint symptoms before starting therapy gives clinicians a reference point to distinguish drug effects from training-related changes. The FDA label for somatropin products (e.g., Genotropin, Norditropin) notes that doses should be adjusted based on clinical response and IGF-1, not titrated to an exercise performance endpoint [23].